Fact-checked by Grok 2 weeks ago

CD24

CD24 is a small, heavily glycosylated sialoglycoprotein encoded by the CD24 gene on chromosome 6q21, consisting of a 32-amino-acid mature peptide anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) linkage, and it is expressed on the surface of mature granulocytes, B lymphocytes, epithelial cells, neurons, and muscle cells, where it modulates growth and differentiation signals to these cell types. As a mucin-like adhesion molecule, CD24 facilitates cell-cell interactions and signaling pathways, including those involving protein tyrosine kinases and Wnt signaling, contributing to processes such as cell adhesion, migration, and immune regulation. Structurally, CD24 features a short peptide backbone with extensive O-linked glycosylation, which accounts for much of its molecular weight (approximately 40-50 kDa despite the small core), and its GPI anchor allows it to be shed or released in soluble forms under certain conditions. Expression of CD24 is developmentally regulated, appearing early in B-cell maturation and persisting on mature immune cells, while it is also found in non-immune tissues like the thyroid and esophagus at high levels. In healthy tissues, CD24 serves as a costimulatory molecule for T-cell activation and supports B-cell receptor transport, enhancing adaptive immune responses in lymphoid organs and specific target tissues such as the brain and skin. Beyond immunity, CD24 plays critical roles in inflammation by interacting with Siglec-10 (or Siglec-G in mice) to distinguish danger-associated molecular patterns from pathogens, thereby repressing excessive inflammatory responses and preventing tissue damage. In autoimmunity, genetic variations in CD24, such as the P170 and P1527 polymorphisms, are associated with increased susceptibility to diseases including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, while CD24 deficiency in models protects against experimental autoimmune conditions like encephalomyelitis. In cancer, CD24 is frequently overexpressed in malignancies such as , , colorectal, ovarian, and pancreatic tumors, where it promotes tumor , , , and immune evasion by inhibiting macrophage and through Siglec-10 binding. Its high expression correlates with poor prognosis and is linked to oncogenic pathways like /STAT3 and EGFR/HER2 signaling, positioning CD24 as a potential and therapeutic target, with ongoing clinical trials exploring anti-CD24 antibodies and CAR-T cell therapies to enhance antitumor immunity.

Discovery and Nomenclature

Historical Discovery

The discovery of CD24 began in 1978 when and colleagues identified it as a heat-stable antigen on murine lymphocytes using monoclonal antibodies generated against mouse thymocytes and splenocytes. This antigen, initially termed the heat-stable antigen (HSA) due to its resistance to heat inactivation, was recognized as a marker prominently expressed on immature B and T lymphocytes, distinguishing it from other lymphoid surface molecules. The study highlighted its role in marking early stages of lymphocyte development, laying the foundation for its recognition as a key cellular identifier in . In the late 1980s, further characterization revealed additional contexts for the . In , researchers demonstrated that nectadrin, a previously identified on rodent neural cells and implicated in neural adhesion, was immunologically identical to the murine heat-stable . This connection emerged from experiments showing that monoclonal antibody 79, raised against neural tissues, bound the same as anti-HSA antibodies, suggesting a broader role beyond lymphoid cells. Subsequent early studies, such as those examining patterns, linked CD24 to neural development in , with high expression observed in embryonic tissues during key differentiation phases. Molecular cloning advanced understanding in the early . The murine Cd24 was cloned in through expression cloning of cDNA from lymphoid cells, revealing a small protein core heavily modified by and anchored via (GPI). This work confirmed its identity as the encoding the M1/69-J11d antigens associated with heat-stable properties. Shortly thereafter, in 1991, the human CD24 was cloned by to the murine sequence, establishing it as a B-cell marker in humans and facilitating cross-species comparisons. During this period, CD24 was formally assigned to the system in the 1980s as part of international workshops standardizing leukocyte antigens.

Naming and Classification

The CD24 molecule, officially designated as the , is a cell surface protein widely recognized in immunological and developmental contexts. Its primary aliases include signal transducer CD24, reflecting its role in cellular signaling, as well as heat stable antigen (HSA), particularly in murine studies, and nectadrin, which highlights its expression in neural tissues. These names stem from early characterizations of its biochemical properties and tissue-specific functions, with HSA emphasizing its resistance to heat denaturation during initial purification efforts. The standardized nomenclature "CD24" was assigned as part of the (CD) system during the Second International on Human Leukocyte Differentiation Antigens (HLDA), held in in 1984, where clusters through CD26 were defined. This assignment built on the foundational CD framework established at the First HLDA in in 1982, which introduced the systematic numbering for leukocyte surface antigens to resolve inconsistencies in naming. The HLDA workshops, organized by the Human Cell Differentiation Molecules (HCDM) committee, continue to validate and update CD designations based on reactivity and molecular characterization. In terms of species variations, the murine ortholog (mCD24, also known as HSA or Cd24a) was discovered first in 1978 as a differentiation on immature lymphocytes, serving as an early B-cell marker. The human ortholog was subsequently identified through in 1991, confirming its to the murine protein and establishing CD24 as a conserved across mammals. Orthologs have been sequenced in various , including rats and non-human , with high conservation in the core despite variations in patterns. CD24 is classified biochemically as a (GPI)-anchored sialoglycoprotein within the mucin-type protein family, characterized by its heavily O-glycosylated extracellular domain that contributes to its mucin-like properties and roles. This GPI linkage anchors it to the outer leaflet of the plasma membrane, facilitating its expression on diverse cell types without transmembrane or cytoplasmic domains. The sialoglycoprotein designation arises from its abundant residues, which modulate its interactions with and .

Genetics

Gene Location and Organization

The human CD24 is located on the long arm of at cytogenetic band 6q21, with genomic coordinates spanning from 106,969,831 to 106,976,855 on the reverse strand according to GRCh38/hg38 assembly, encompassing approximately 7 kb of genomic DNA. The exhibits a compact typical of small protein-coding loci, featuring multiple transcript variants due to . The canonical transcript (ENST00000606017.2, also known as CD24-201) consists of two s: the first encodes the N-terminal responsible for directing the protein to the secretory pathway, while the second encodes the mature polypeptide sequence, including the C-terminal for (GPI) anchoring to the . Other variants, such as ENST00000619133.4 (CD24-204), incorporate additional s (up to three in some cases), potentially altering regulatory elements or untranslated regions, though all maintain the core coding frame for the GPI-anchored . Known genetic variants include single nucleotide polymorphisms (SNPs) such as rs8734, which may influence CD24 expression levels. Non-transcribed pseudogenes and homologous sequences related to CD24 are dispersed across the at several loci, including chromosome 1p36, chromosome 15q21, , and chromosome Yq11; these sequences lack functional open reading frames and do not contribute to protein expression. Southern blot analyses have confirmed the multicopy nature of CD24-like elements, with at least five distinct genomic sites identified, underscoring the gene family's expansion through duplication events. Evolutionarily, the CD24 gene is highly conserved among mammals, originating prior to the divergence of reptiles, , and mammals, with orthologs present in diverse species including mice (located on 10). The coding sequence shows substantial preservation of functional motifs, such as sites, with the human and murine proteins exhibiting approximately 30% sequence identity, supporting shared roles in and signaling despite species-specific variations.

Regulation of Gene Expression

The expression of the CD24 gene is primarily regulated at the transcriptional level, particularly in contexts where CD24 upregulation supports and survival. In B cells, CD24 transcription is dynamically controlled during maturation, with high levels in pro-B and immature stages that decline sharply in mature naive B cells, reflecting stage-specific regulatory inputs that link expression to energy metabolism and developmental checkpoints. Epigenetic modifications play a key role in CD24 , including promoter hypermethylation that can silence expression in certain tissues and cancers, such as tumors where hypermethylation correlates with reduced CD24 levels independent of other factors. Conversely, histone acetylation promotes CD24 expression during ; for instance, treatment with inhibitors induces CD24 in embryonal carcinoma cells, shifting fate toward ectodermal lineages by enhancing promoter accessibility. CD24 expression responds to external stimuli in immune cells, exhibiting dynamic changes during inflammatory conditions and B-cell development, though direct induction by specific cytokines like IL-1 or TNF-α remains context-dependent and not universally reported. The produces primarily one major transcript, NM_013230, encoding the full-length preproprotein, with rare variants arising from or alternate 5' exons that yield shorter isoforms of limited functional impact.

Protein Structure

Primary Sequence and Domains

The CD24 protein in humans is encoded by the CD24 gene located on chromosome 6q21. The precursor form consists of 80 , which includes an N-terminal of 26 residues that is cleaved during processing, resulting in a mature protein of 32 . This small core polypeptide lacks a and has no intracellular signaling domain, distinguishing it from typical integral membrane proteins. The primary sequence of mature CD24 features a central mucin-like region characterized by a high content of serine and threonine residues, which serve as potential sites for , with approximately 16 such motifs identified. This region confers a heavily glycosylated, extended conformation to the protein, contributing to its role as a sialoglycoprotein. Toward the , a GPI anchor signal sequence is present, which facilitates post-translational attachment to the via without direct transmembrane integration. The core unglycosylated protein has a calculated molecular weight of approximately 3.5 , though the apparent molecular weight observed in cells ranges from 20 to 70 due to extensive .

Anchoring and Modifications

CD24 is anchored to the outer leaflet of the plasma via a (GPI) anchor, a that occurs in the (ER). The GPI anchor is covalently attached to the C-terminal ω-site of the mature CD24 protein, typically a serine residue, by the GPI transamidase complex, which cleaves the C-terminal GPI and links the protein to the preformed GPI core. This core consists of phosphate linked to a trimannose-glucosamine- structure, with the phosphatidylinositol moiety embedding into the via diacylglycerol or other chains, enabling stable membrane integration without transmembrane or cytoplasmic domains. The GPI anchor facilitates CD24's localization to cholesterol- and sphingolipid-enriched rafts, detergent-resistant domains that concentrate signaling molecules and promote lateral protein interactions on the cell surface. This raft association enhances CD24's role in modulating receptor clustering and , as the saturated fatty acids in the GPI lipid tail promote ordered microdomains. In addition to GPI anchoring, CD24 undergoes extensive , which dominates its post-translational modifications and defines its functional properties. The protein core, comprising only about 10% of the total mass, is heavily modified with mucin-type O-linked glycans at up to 14 serine/ sites, primarily initiated by (GalNAc) addition in the Golgi apparatus; N-linked is minimal, occurring at just two sites. These O-glycans often terminate in residues (, Neu5Ac) in α2,3- or α2,6-linkages, forming structures like sialyl-T (Neu5Acα2,3/6Galβ1,3GalNAc) and , which contribute approximately 90% of CD24's molecular weight (30–80 kDa, varying by ) and mediate interactions with such as and selectins. Glycosylation processing begins in the with core N-glycan addition and GPI attachment, followed by O-glycan initiation and elaboration in the Golgi, where sialyltransferases from the ST3Gal family (e.g., ST3Gal-I to VI) catalyze the terminal sialylation of Galβ1,3GalNAc motifs to generate α2,3-linked sialic acids. Glycan patterns exhibit cell-type specificity, influenced by differential expression of glycosyltransferases; for instance, neural tissues favor α2,3-sialylated O-glycans for molecule binding, while cancer cells often display hypersialylation due to upregulated ST3Gal enzymes, altering CD24's charge and conformation. The GPI linkage confers dynamic stability to CD24, allowing regulated shedding into a soluble form via cleavage by phosphatidylinositol-specific (PI-PLC), which hydrolyzes the anchor's inositol-phosphate bond and releases glycosylated CD24 ectodomains into the . This shedding mechanism, also involving matrix metalloproteinases or exosome packaging, modulates surface levels of CD24 and contributes to its presence in as a potential , particularly in inflammatory or neoplastic contexts.

Expression Patterns

In Normal Tissues and Cells

CD24 exhibits a restricted expression pattern in healthy adult human tissues, predominantly in immune and epithelial compartments. It is highly abundant in lymphoid organs such as the spleen and lymph nodes, where it marks mature immune cells, while showing low levels in the brain, liver, and heart. Moderate expression occurs in the kidney and urinary bladder, reflecting its presence on specific epithelial layers, with low expression in the pancreas overall, though detectable in acinar cells per single-cell data. High expression is also observed in the thyroid gland. In immune cells, CD24 is strongly expressed on mature B lymphocytes, serving as a key surface marker for their identity and function. Granulocytes, particularly neutrophils, display high CD24 levels starting from the stage of maturation onward, distinguishing them from earlier precursors like promyelocytes. In contrast, T cells show minimal expression on peripheral mature subsets, with only weak detection, while monocytes exhibit moderate levels. Epithelial cells in select organs also express CD24 prominently, including those in the , tubules, and urothelium, where it associates with differentiated or progenitor-like populations. A subset of neurons in the adult shows low expression, contributing to limited neural involvement. The displays moderate to low CD24, primarily in cell-enriched crypt bases. Single-cell RNA sequencing data from normal tissues reinforces this specificity, with CD24 transcripts clustering highly in and populations (mean expression up to 1260 nCPM in granulocytes) alongside epithelial markers in secretory and squamous cells (up to 14,637 nCPM in esophageal ).

During Development and Differentiation

CD24 expression is upregulated during B-cell maturation, beginning in pro-B cells within the and persisting through the pre-B to mature B-cell stages, where it serves as a key surface marker for these developmental transitions. This pattern reflects CD24's role in early B-lymphocyte commitment, with high levels maintained on mature resting B cells before downregulation in terminally differentiated plasma cells. In T-cell development, CD24 expression is transient in early progenitors, appearing at higher levels in immature thymocytes to support clustering and initial steps before declining in mature T cells. Similarly, CD24 is highly expressed during , emerging at the myelocytic stage in granulocytes and contributing to the maturation process in these innate immune cells. In neural development, CD24 is prominently expressed on neuroblasts and plays a critical role during , particularly in mice where it is known as nectadrin, a GPI-anchored that modulates neurite outgrowth and interactions with molecules like L1. This expression facilitates reciprocal signaling between neurons and their microenvironment, influencing and circuit formation in the developing . CD24 levels peak in precursors, where it is strongly detected in the external granule layer during proliferation and migration, before tapering as these cells integrate into the cerebellar cortex. During embryonic development, CD24 appears early in the , correlating with the upregulation of neural markers in differentiating embryonic and marking teratogen-sensitive fetal populations. Its expression later extends to hematopoietic lineages, where it emerges in progenitor cells of the to aid lineage commitment. In , CD24 influences the transition from pluripotent states to committed lineages, particularly in neural and hematopoietic contexts, by regulating and adhesion in these dynamic processes. CD24 is induced in and epithelial cells during , serving as a marker that emerges in the suprabasal layers of the and bulge regions as cells commit to terminal programs. This upregulation supports the organized layering and barrier formation in developing equivalents, with CD24-positive demonstrating enhanced potential in organotypic cultures.

Biological Functions

In Immune Regulation

CD24 plays a in modulating B-cell responses, where it is highly expressed on immature and mature B cells but downregulated during terminal differentiation. Engagement of CD24 enhances antigen-dependent B-cell by altering the localization of the (BCR) within rafts, thereby facilitating intracellular signaling cascades that promote cell growth and survival in response to BCR stimulation. Additionally, CD24 prevents the terminal differentiation of B cells into antibody-secreting s, maintaining a pool of undifferentiated B cells essential for ongoing immune responses; this is evidenced by its absence on mature s and the observation that CD24 loss correlates with formation. These functions position CD24 as a rheostat for B-cell maturation and activation, balancing against in early developmental stages. In neutrophils, another key immune cell type expressing CD24, cross-linking of the molecule triggers caspase-dependent through mitochondrial membrane depolarization and production, thereby regulating neutrophil lifespan and preventing excessive . This apoptotic pathway is impaired in patients, where CD24 expression and function are downregulated, leading to delayed neutrophil death, prolonged tissue infiltration, and sustained inflammatory responses that exacerbate organ damage. Such dysregulation highlights CD24's role in resolving acute by promoting timely neutrophil clearance. CD24 also contributes to immune cell trafficking by mediating leukocyte and . As a glycosylated for P-selectin on activated and platelets, CD24 facilitates the initial rolling of leukocytes along the vascular under , a prerequisite for subsequent firm and to sites of or . This regulates leukocyte without directly activating , ensuring efficient immune surveillance while minimizing non-specific tissue damage. Furthermore, CD24 serves as an by interacting with Siglec-10 to repress tissue damage-induced immune responses and distinguish self from danger signals, thereby preventing excessive inflammatory responses to host-derived ligands while allowing responses to pathogens. This mechanism helps maintain by modulating activity during .

In Neural and Tissue Homeostasis

CD24, also known as nectadrin in , plays a critical role in neural development by facilitating and signaling processes essential for neuronal migration and growth. In the , CD24 modulates the adhesion and neurite outgrowth of granule cells, contributing to their proper positioning and extension during development. Specifically, CD24 interacts in cis with the L1 on the same cell surface, enabling cooperative signaling that promotes outgrowth and neuronal survival in models. This nectadrin-mediated interaction is transient, with CD24 expression peaking during early neural differentiation and declining as neurons mature, thereby supporting the dynamic remodeling required for formation. Beyond neural tissues, CD24 contributes to the maintenance of epithelial integrity in various organs by regulating populations and cell-cell interactions. In the intestine, CD24 serves as a surface marker for enriching intestinal epithelial stem cells (IESCs), particularly those co-expressing , which are vital for crypt-villus architecture and ongoing tissue renewal. CD24-positive cells in the and colon exhibit stem-like properties, facilitating the isolation of + progenitors that drive epithelial through and . Similarly, in the skin, CD24 is expressed on , where it is involved in and signaling. CD24 also promotes cell-cell in renal epithelia, aiding in the structural of these s. In the , CD24+ epithelial progenitors give rise to organoids displaying mature tubular features, including tight and adherens junctions that ensure compartmentalization and . Furthermore, CD24 influences homeostatic signaling in epithelial progenitors by integrating and cues. In intestinal and airway epithelia, CD24+ progenitors respond to niche signals, promoting balanced and to maintain architecture. Its GPI anchoring enables rapid dynamics, allowing CD24 to transduce signals from the to intracellular pathways that regulate progenitor fate.

Signaling Mechanisms

Key Pathways Activated

CD24, a (GPI)-anchored protein lacking an intracellular signaling domain, transduces signals primarily through clustering in lipid rafts upon ligand binding or antibody-mediated cross-linking, recruiting associated kinases and adaptors to initiate downstream cascades. One primary pathway activated by CD24 involves Src family kinases. Cross-linking of CD24 recruits and activates Src kinases within lipid rafts, leading to phosphorylation of downstream targets and subsequent activation of the MAPK/ERK pathway, which promotes and survival. For instance, in various cell types, CD24 engagement enhances Src activity, resulting in ERK1/2 and changes supporting growth. CD24 also modulates the RhoA/ pathway, influencing cytoskeletal dynamics and . By associating with , CD24 inhibits EGFR internalization in a RhoA-dependent manner, thereby sustaining RhoA activation and downstream -mediated of light chain, which regulates actin- contractility and cellular motility. This mechanism facilitates activation and directional movement without directly altering RhoA expression levels. In the Wnt/β-catenin pathway, CD24 promotes stabilization and nuclear translocation of β-catenin. CD24 engagement disrupts the β-catenin destruction complex, preventing its degradation and enabling accumulation in the followed by nuclear import, where it interacts with TCF/LEF transcription factors to activate target genes involved in and proliferation. This activation occurs independently of canonical Wnt ligands in some contexts, highlighting CD24's role as a modulator. CD24 also contributes to the Hippo-YAP signaling pathway, where it enhances phagocytic activity regulation in macrophages and supports tumor immune evasion by modulating YAP-mediated transcription of immunosuppressive factors. Regarding , CD24 ligation in triggers a caspase-dependent pathway culminating in caspase-3 . Cross-linking induces mitochondrial outer and production, leading to release and sequential of and caspase-3, thereby executing through GPI raft-mediated clustering. This process is impaired under inflammatory conditions such as but represents a key regulatory mechanism for .

Molecular Interactions

CD24, a heavily glycosylated mucin-like protein anchored to the via (GPI), primarily engages binding partners through its sialylated motifs rather than direct protein-protein interactions, as its core polypeptide is largely obscured by . A key inhibitory interaction occurs between CD24 and Siglec-10, a sialic acid-binding immunoglobulin-like expressed on macrophages and other immune cells; this binding recruits immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and associated phosphatases, such as SHP-1, to suppress phagocytic activity and dampen innate immune responses. This interaction also helps regulate responses to damage-associated molecular patterns (DAMPs), including heat shock proteins like and , by repressing excessive without direct binding to the HSPs. CD24 serves as a for P-selectin, an adhesion molecule on activated endothelial cells and platelets, facilitating leukocyte rolling and tethering to the vascular endothelium through recognition of CD24's sialylated and sulfated structures. In terms of integrin modulation, CD24 promotes the translocation of β1 into rafts, enhancing their clustering and signaling capacity without direct binding, thereby influencing and dynamics. CD24 associates with epidermal growth factor receptor (EGFR) in lipid raft microdomains, inhibiting EGFR endocytosis and degradation in a RhoA-dependent manner to sustain EGF-induced signaling. Direct binding between CD24 and β-catenin has been demonstrated via immunoprecipitation, enabling CD24 to stabilize and promote nuclear translocation of β-catenin, thereby interfacing with Wnt signaling components. These interactions often occur within lipid rafts, where CD24 can briefly reference activation of Src family kinases to amplify downstream effects, though full pathway details lie beyond this scope.

Role in Diseases

In Cancer Progression

CD24 contributes to cancer progression by promoting tumor cell proliferation and invasion through multiple mechanisms, including the upregulation of epithelial-mesenchymal transition (EMT) via RhoA signaling. In hepatocellular carcinoma (HCC), ovarian cancer, and breast cancer, CD24 serves as a marker for cancer stem cells (CSCs), enhancing self-renewal and resistance to chemotherapy and radiation. For instance, CD24-positive CSCs in HCC activate STAT3-Nanog pathways to maintain stemness properties, while in ovarian cancer, knockdown of CD24 reduces tumor progression and invasion. Similarly, in breast cancer, CD24 overexpression correlates with increased proliferation via Src/STAT3 and EGFR pathways, fostering aggressive tumor growth. CD24 facilitates by enhancing , adhesion to proteins, and resistance to anoikis, the triggered by detachment from the matrix. These effects enable tumor cells to disseminate more effectively, with high CD24 expression correlating with positivity and poor overall prognosis in cancers such as and esophageal . Studies demonstrate that CD24-mediated interactions with P-selectin and further promote migratory behavior, contributing to metastatic spread across various solid tumors. A critical aspect of CD24's role in cancer progression is immune evasion, primarily through the CD24-Siglec-10 axis, which delivers an inhibitory "do not eat me" signal to macrophages, suppressing of tumor cells. This interaction inhibits innate immune clearance and reduces natural killer cell cytotoxicity, allowing tumors to persist. CD24 is overexpressed in approximately 70% of solid cancers, including and ovarian tumors, where it drives immune escape and correlates with worse clinical outcomes. In specific cancers, CD24 overexpression is notably associated with progression in non-small cell lung cancer (NSCLC), particularly the subtype, where it acts as an independent prognostic marker for poor survival and resistance to therapies like . In , CD24 marks dormant, drug-resistant CSCs enriched in residual disease post-treatment, driving aggressive relapse and tumor spread through stem-like features and pathways. Additionally, soluble CD24 in serum serves as a potential for monitoring progression in cancers such as HCC and ovarian , reflecting tumor burden and prognostic risk.

In Inflammatory and Autoimmune Disorders

CD24 exhibits a in inflammatory processes, acting as both pro- and depending on context. In pro-inflammatory scenarios, CD24 promotes immune cell survival and activation, contributing to excessive inflammation in conditions like . Conversely, sialylated CD24 (SialoCD24) interacts with Siglec-10 on innate immune cells to dampen responses to danger-associated molecular patterns (DAMPs), mitigating tissue damage without impairing defense. Soluble CD24 (sCD24), often fused with Fc (CD24Fc), serves as a modulator by forming complexes with DAMPs like and heat shock proteins, suppressing storms in models of , graft-versus-host disease, and viral infections. In , CD24 cross-ligation induces caspase-dependent in neutrophils via mitochondrial depolarization and production, promoting resolution of . However, neutrophils from patients show downregulated CD24 expression, impairing this apoptotic pathway and leading to prolonged survival, accumulation, and organ damage. This defect exacerbates , as suggested by analyses indicating altered responses to CD24 triggering in septic neutrophils compared to healthy controls. CD24 also influences autoimmunity through genetic variants and expression changes. The Ala57Val polymorphism (rs8734) in the CD24 gene increases susceptibility to multiple sclerosis (MS), with the Val/Val genotype conferring higher risk (OR = 2.30 in Caucasians) by altering thymocyte deletion of autoreactive T cells, thus enhancing autoimmunity. Similarly, this SNP associates with systemic lupus erythematosus (SLE) risk (OR = 1.71 overall), though evidence is less consistent across cohorts. In rheumatoid arthritis (RA), CD24 expression is upregulated on synovial fluid granulocytes compared to peripheral blood cells, indicating activation and contributing to joint inflammation; additionally, CD24hi B cells (CD19+CD24hiCD27+) accumulate in synovial fluid, correlating with bone destruction. In (IBD), CD24 is upregulated in affected intestinal tissues (observed in all examined cases), absent in normal mucosa, and regulated by Wnt signaling. This overexpression enhances epithelial cell motility, invasion, and colony formation without affecting proliferation or , potentially aiding repair but also promoting chronic inflammation. Genetic polymorphisms like C170T further link CD24 to IBD susceptibility, particularly . In autoimmune hepatitis, CD24 aggravates acute liver injury by promoting IFN-γ production from CD4+ T cells via STAT1 phosphorylation. CD24-deficient mice exhibit reduced serum IFN-γ, lower ALT levels, and less hepatic damage after concanavalin A challenge, highlighting its pro-inflammatory role in T cell-mediated autoimmunity.

Clinical Relevance

As a Biomarker

CD24 serves as a prognostic biomarker in multiple cancer types, where elevated tissue expression or soluble levels in circulation correlate with adverse outcomes. In breast cancer, CD24 is abundantly expressed on carcinoma cells via immunohistochemistry (IHC), with high membranous and cytoplasmic staining indicating tumor progression and poor differentiation. Similarly, in ovarian cancer, increased soluble CD24 in plasma and exosomes is an independent predictor of poor prognosis, reflecting tumor burden and metastasis potential. For non-small cell lung cancer (NSCLC), particularly adenocarcinoma subtypes, high CD24 expression by IHC is associated with disease progression and reduced cancer-specific survival. As a marker of cancer stem cell-like properties, CD24 co-expression with other surface antigens (e.g., CD44) via IHC or flow cytometry helps identify stemness, where scores exceeding 20% positive tumor cells often denote aggressive phenotypes and therapy resistance. Recent studies as of 2025 have linked high CD24 expression to poor outcomes in newly diagnosed multiple myeloma. In inflammatory conditions, CD24 expression on immune cells provides diagnostic and prognostic value. Elevated neutrophil CD24 surface expression, measured by flow cytometry, combined with other leukocyte markers, predicts sepsis severity and clinical deterioration in at-risk patients, offering early warning for intensive care needs. In bladder cancer, urinary CD24 mRNA or protein levels, detected via quantitative PCR (qPCR) or exosome analysis, form part of non-invasive biomarker panels for monitoring non-muscle-invasive disease recurrence and progression. Additionally, elevated circulating CD24/Siglec-10 levels as of October 2025 predict poor neurological prognosis and mortality post-cardiac arrest. For autoimmune disorders, genetic and cellular biomarkers involving CD24 aid in susceptibility assessment and disease monitoring. The CD24 P170 polymorphism (rs8734), particularly the TT genotype, is associated with increased (MS) susceptibility and faster disease progression, as determined by studies. Additionally, quantification of CD19+CD24hiCD38hi regulatory B cells reveals functional impairment in conditions like systemic lupus erythematosus (SLE), where reduced frequencies correlate with heightened disease activity and poor response to therapy. Detection of CD24 relies on established methods tailored to sample type. Soluble CD24 in serum or plasma is quantified using enzyme-linked immunosorbent assay (ELISA), enabling sensitive measurement of circulating levels for prognostic evaluation. Tissue expression is assessed via IHC on biopsies, with staining intensity and percentage of positive cells scored semi-quantitatively (e.g., cutoff >20% for high expression in tumors). For molecular analysis, qPCR amplifies CD24 mRNA from tissue or urine, with established cutoffs like relative expression >0.05 signaling pathological elevation.

Therapeutic Targeting

Therapeutic strategies targeting CD24 primarily focus on its role as an that inhibits via interaction with Siglec-10 on macrophages, thereby promoting tumor immune evasion. Blocking this interaction with anti-CD24 monoclonal antibodies enhances macrophage-mediated tumor cell clearance, particularly in solid tumors where CD24 is overexpressed. Early preclinical studies demonstrated the efficacy of the anti-CD24 SWA11 in retarding tumor growth and metastasis in xenograft models of colorectal, pancreatic, and s by altering the intratumoral microenvironment and synergizing with chemotherapies such as and . Humanized antibodies such as ATG-031 and IMM47 have entered clinical evaluation; these agents disrupt CD24-Siglec-10 binding to stimulate . ATG-031 is being assessed in a phase 1 trial (NCT06028373) for safety, tolerability, and preliminary efficacy in patients with advanced solid tumors or B-cell , with estimated completion in June 2027 and no interim results posted as of November 2025. IMM47 is under investigation in a phase 1 trial (NCT05985083) for advanced solid tumors. Similarly, PHST001, another anti-CD24 , received FDA fast track designation for advanced in June 2025 and is under investigation in an ongoing phase 1 trial (NCT06840886) enrolling patients with relapsed/refractory solid tumors, including , to evaluate dose escalation and expansion cohorts, with no interim results posted as of November 2025. Chimeric antigen receptor () T-cell and natural killer () cell therapies targeting CD24 have shown promise in preclinical models for cancers with high CD24 expression, such as and . CD24-specific CAR-T cells exhibit potent cytotoxicity against tumor cells, mediating long-term antitumor effects through endogenous immune activation, and bispecific constructs like BCMA/CD24 CAR-T cells enhance tumor clearance by recruiting macrophages without significant off-target effects and . These approaches are being explored in combination with PD-1 inhibitors to overcome immunosuppressive microenvironments, as CD24 blockade complements T-cell checkpoint inhibition. No CD24-targeted CAR-T trials for have advanced to clinical stages as of 2025, though preclinical data support their potential application. Gene therapy approaches, such as (shRNA)-mediated silencing of CD24, have demonstrated reduced tumor growth, microvessel density, and in preclinical ovarian and models by inhibiting and inducing . For instance, CD24 shRNA delivery suppressed ovarian tumor progression and enhanced sensitivity to p53-restoring agents like PRIMA-1 in cells. These strategies remain investigational, with no clinical trials reported to date. A key challenge in CD24 targeting is on-target toxicity due to its expression on normal B cells, which could lead to B-cell depletion and ; however, early clinical data from ATG-031, IMM47, and PHST001 trials indicate manageable safety profiles, potentially mitigated by tumor-selective overexpression. Ongoing efforts aim to refine specificity and designs to minimize off-tumor effects while maximizing antitumor activity.

References

  1. [1]
    100133941 - Gene ResultCD24 CD24 molecule [ (human)] - NCBI
    Aug 19, 2025 · This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and B cells and modulates growth and differentiation signals to these cells.
  2. [2]
    CD24: A Novel Target for Cancer Immunotherapy - PubMed Central
    CD24 is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells.
  3. [3]
    Tumour biological aspects of CD24, a mucin-like adhesion molecule
    CD24 is a molecule that recently has raised considerable attention in tumour biology. It is involved in cell adhesion and metastatic tumour spread.
  4. [4]
    The CD24 Protein Inducible Expression System Is an Ideal Tool to ...
    CD24 is a cell surface, heavily glycosylated glycosylphosphatidylinositol-anchored mucin-like protein that is overexpressed in various human malignancies. To ...
  5. [5]
    CD24: from A to Z - PMC - PubMed Central - NIH
    In this paper, we will provide a brief summary of the roles for CD24 in adaptive immunity, inflammation, autoimmunity and cancer.
  6. [6]
    From mechanism to therapy: the journey of CD24 in cancer - PMC
    In summary, CD24 is a cell surface protein that interacts with several receptor proteins, including Siglec-10, Siglec-15, and the NKG2D receptor. These ...
  7. [7]
    Novel insights into the function of CD24: A driving force in cancer
    Feb 1, 2021 · In cancer, CD24 is a regulator of cell migration, invasion and proliferation. Its expression is associated with poor prognosis and it is used as ...
  8. [8]
    Checkpoint CD24 function on tumor and immunotherapy - PubMed
    Feb 29, 2024 · CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells.
  9. [9]
    From mechanism to therapy: the journey of CD24 in cancer - PubMed
    May 31, 2024 · CD24 is a glycosylphosphatidylinositol-anchored protein that is expressed in a wide range of tissues and cell types.<|control11|><|separator|>
  10. [10]
    Expression cloning of a cDNA encoding M1/69-J11d heat ... - PubMed
    Sep 15, 1990 · The cloned cDNA is a copy of a gene that is transcribed in M1/69-J11d+ lymphoid, myeloid, and erythroid cells. This gene could be responsible ...
  11. [11]
    CD24, a signal transducer modulating B cell activation responses, is ...
    CD24 is a signal-transducing molecule on the surfaces of most human B cells that can modulate their response to activation signals.
  12. [12]
  13. [13]
    Signal transducer CD24 - Homo sapiens (Human) - UniProt
    Mar 28, 2018 · Recommended name. Signal transducer CD24. Alternative names. Small cell lung carcinoma cluster 4 antigen ; Taxonomic identifier. 9606 (NCBI ).
  14. [14]
    Human Leukocyte Differentiation Antigen Workshop Ⅱ/ HLDA2
    The Human Leukocyte Differentiation Antigen workshop Ⅱ (HLDA2), held in Boston, USA, in 1984. The purpose of HLDA2 was to continue to define clusters of ...Missing: second | Show results with:second
  15. [15]
    The Human Leucocyte Differentiation Antigens (HLDA) Workshops
    Here we review the achievements of the HLDA Workshops and provide links to information on CD molecules and antibodies against them.Missing: CD24 | Show results with:CD24
  16. [16]
    Targeting CD24 in Cancer Immunotherapy - MDPI
    In 1978, mouse heat-stable antigen (HSA), a homologue of human CD24, was discovered and named after its heat resistance [2]. Over time, it has become ...
  17. [17]
    Novel insights into the function of CD24: A driving force in cancer
    Aug 13, 2020 · CD24 is a regulator of cell migration, invasion and proliferation. Its expression is associated with poor prognosis and it is used as cancer stemness marker.<|control11|><|separator|>
  18. [18]
    Analysis of the structure, evolution, and expression of CD24, an ...
    Sep 30, 2016 · CD24 arose prior to the reptilian-avian divergence and is conserved across many mammalian species, although we were unable to identify CD24 in ...
  19. [19]
    CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on ...
    May 1, 1997 · We report that CD24, a mucin-type glycosylphosphatidylinositol-linked cell surface molecule on human neutrophils, pre B lymphocytes, and many tumors can ...
  20. [20]
  21. [21]
    Analysis of the structure, evolution, and expression of CD24, an ...
    Among these factors, CD24 was first identified as a heat-stable antigen in 1978 and first successfully cloned in 1990. Thereafter, its functional roles have ...
  22. [22]
    CD24 Gene - GeneCards | CD24 Protein | CD24 Antibody
    This gene was present in the common ancestor of human and mouse. Orthologs for CD24 Gene.
  23. [23]
    Gene: CD24 (ENSG00000272398) - Summary - Homo_sapiens
    Chromosome 6: 106,969,831-106,975,627 reverse strand. GRCh38:CM000668.2. About this gene. This gene has 8 transcripts (splice variants) and 153 orthologues.
  24. [24]
    Transcript: ENST00000606017.2 (CD24-201) - Summary - Ensembl
    Chromosome 6: 106,969,831-106,974,729 reverse strand. ... This transcript has 2 exons, is annotated with 17 domains and features, is associated with 2074 variant ...
  25. [25]
    Mapping of CD24 and homologous sequences to multiple ... - PubMed
    Jul 1, 1994 · Southern blot analysis suggested the presence of multiple CD24 related sequences in the human genome. We have now mapped CD24 homologous ...Missing: evolutionary conservation identity
  26. [26]
    Analysis of the structure, evolution, and expression of CD24, an ...
    Sep 30, 2016 · Research paper. Analysis of the structure, evolution, and expression of CD24, an important regulator of cell fate.
  27. [27]
    CD24 Expression and B Cell Maturation Shows a Novel Link ... - NIH
    Oct 22, 2018 · We suggest that CD24 expression may reflect variations in energy metabolism on different B cell subsets.
  28. [28]
    Division of Cancer Control & Population Sciences ... - Funding History
    Our preliminary studies gave exciting evidence that CD24 is epigenetically silenced in breast tumors by promoter hypermethylation. To date there has been no ...
  29. [29]
    The signal transducer CD24 suppresses the germ cell program and ...
    The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas.
  30. [30]
  31. [31]
    Entry - *600074 - CD24 ANTIGEN - OMIM
    (1994) cloned the human CD24 gene. Using microarray analysis, Jevsek et al. (2006) found that Cd24 was expressed in myofiber synaptic nuclei in embryonic ...
  32. [32]
    Analysis of Recombinant CD24 Glycans by MALDI-TOF-MS Reveals ...
    From the CD24 amino acid sequence, it has four potential N-glycosylation sites and a total of sixteen serine and threonine amino acids which are potential O- ...
  33. [33]
  34. [34]
    Biosynthesis and biology of mammalian GPI-anchored proteins
    Mar 11, 2020 · The GPI consists of the conserved core glycan, phosphatidylinositol and glycan side chains. The entire GPI-AP is anchored to the outer leaflet ...Introduction · Biogenesis of GPI-APs: post... · GPI-AP maturation pathway...
  35. [35]
    CD24 induces localization of beta1 integrin to lipid raft domains
    Jan 4, 2008 · The expression of the glycosyl phosphatidylinositol (GPI)-anchored protein CD24 correlates with poor prognosis in a variety of carcinomas.
  36. [36]
    Glycosylation Modulates Plasma Membrane Trafficking of CD24 in ...
    Jul 29, 2021 · The premature CD24 molecule consists of 80 amino acids ... sialic acid residues are present, and therefore the molecule is probably functional.
  37. [37]
    O-glycosylation pattern of CD24 from mouse brain - PubMed
    Our present study provides evidence that interaction of CD24 with the cell adhesion molecule L1 is mediated by O-linked glycans carrying alpha2,3-linked sialic ...
  38. [38]
    CD24 protein expression summary
    7:Adipose tissue - Mixed function 26:Adrenal gland - Steroid metabolism 77:Bone marrow - Cell proliferation 6:Bone marrow - Innate immune responseMissing: exons | Show results with:exons
  39. [39]
    CD24 is a marker for the myelocytic stage of development - PubMed
    CD24 is expressed on bone marrow granulocytes in a pattern that is similar to CD11b while much different than the more mature markers, CD16b and CD35.
  40. [40]
    Single cell type - CD24 - The Human Protein Atlas
    ### Summary of CD24 RNA Expression in Single-Cell Data from Normal Tissues
  41. [41]
    Expression of CD24, a Stem Cell Marker, in Pancreatic and Small ...
    CD24 has been considered a normal and cancer stem cell marker. Potential intestinal stem cells weakly express CD24. In the pancreas, CD24 is a possible cancer ...
  42. [42]
    Assessment of CD24 expression on bone marrow neutrophilic ...
    In this study, we have confirmed that CD24 is expressed on neutrophilic granulocytes from the myelocytic stage on- ward and is usually not expressed on ...
  43. [43]
    mCD24, a Glycoprotein Transiently Expressed by Neurons, Is an ...
    In the nervous system, the function of mCD24 has not been determined, but its tran- sient expression by neurons suggests that it may be involved in axon growth ...
  44. [44]
    The CD24 surface antigen in neural development and disease
    Conserved across many mammalian species (Ayre et al., 2016), CD24 was first identified in mice in 1978 and named the heat stable antigen for its resistance to ...
  45. [45]
    Gene expression of CD24 core peptide molecule in developing ...
    Recently, M l / J l l d has been molecularly cloned (Kay et al., 1990), revealing that MliJlld is a heavily gly- cosylated membrane protein anchored by GPI ...
  46. [46]
    CD15, CD24, and CD29 Define a Surface Biomarker Code for ...
    We identify a CD surface antigen code for the neural lineage based on combinatorial flow cytometric analysis of three distinct populations derived from human ...
  47. [47]
    CD24 tracks divergent pluripotent states in mouse and human cells
    Jun 16, 2015 · CD24 is a conserved marker for tracking divergent states in both reprogramming and standard pluripotent culture.
  48. [48]
    CD24 (heat stable antigen, nectadrin), a novel keratinocyte ...
    CD24, a glycoprotein thought to be involved in cell-cell adhesion and signalling, is highly expressed in keratinocytes located in the bulge area of the rat ...
  49. [49]
    Safe Selection of Genetically Manipulated Human Primary ...
    Aug 21, 2007 · Epidermis generated with CD24+/GFP+ keratinocytes presents normal features of stratification and differentiation. The presence of basal ...Missing: induction | Show results with:induction
  50. [50]
    CD24: A Rheostat That Modulates Cell Surface Receptor Signaling ...
    Dec 27, 2016 · Studies in B cells showed that CD24 alters the localization of the B Cell Receptor (BCR) and associated intracellular signaling proteins within ...
  51. [51]
    Checkpoint CD24 function on tumor and immunotherapy - PMC
    Feb 29, 2024 · CD24 was initially recognized as a marker for B cells. It is highly expressed in B cell progenitors but not in terminally differentiated plasma ...
  52. [52]
    CD24 as a Potential Therapeutic Target in Patients with B-Cell ...
    Nov 18, 2022 · These data suggest that CD24, in concert with Siglec-10, acts as a mechanism to regulate self/non-self-interactions by the innate immune system.Missing: Sp1 Sp3
  53. [53]
    CD24-triggered caspase-dependent apoptosis via mitochondrial ...
    Mar 1, 2014 · We observed that CD24 expression (at both mRNA and protein levels) was significantly downregulated in neutrophils from sepsis patients but not ...<|separator|>
  54. [54]
    CD24-mediated neutrophil death in inflammation: ex vivo study ...
    CD24, a cell-surface protein, is linked to neutrophil apoptosis. CD24 cross-ligation induces caspase-independent apoptosis in neutrophils. This study is the ...
  55. [55]
    CD24, a mucin-type glycoprotein, is a ligand for P-selectin ... - PubMed
    The major ligand for P-selectin on leukocytes is P-selectin glycoprotein ligand-1 (PSGL-1). P-selectin can also bind to carcinoma cells, but the nature of the ...Missing: migration | Show results with:migration
  56. [56]
    P-selectin glycoprotein ligand-1–deficient mice have impaired ... - NIH
    CD24, a heavily O-glycosylated protein on murine leukocytes, has been shown to bind to P-selectin (24). However, incubation of PSGL-1–/– leukocytes with two ...
  57. [57]
    CD24 signalling through macrophage Siglec-10 is a new target for ...
    Jan 31, 2020 · Here we show that CD24 can be the dominant innate immune checkpoint in ovarian cancer and breast cancer, and is a new, promising target for ...
  58. [58]
    CD24 — a novel 'don't eat me' signal | Nature Reviews Cancer
    Aug 12, 2019 · A new study now reports that one such 'don't eat me' signal, CD24, orchestrates a novel innate immune checkpoint through interaction with the inhibitory ...
  59. [59]
    High N-glycan multiplicity is critical for neuronal adhesion and ...
    Oct 12, 2018 · ... CD24 modulating cell adhesion and neurite outgrowth of cerebellar ... (2013) Glial scaffold required for cerebellar granule cell migration ...
  60. [60]
    Neural cell recognition molecule L1: relating biological complexity to ...
    Apr 1, 2000 · ) Evidence for cis interaction and cooperative signalling by the heat-stable antigen nectadrin (murine CD24) and the cell adhesion molecule L1 ...
  61. [61]
    Sox9 expression marks a subset of CD24-expressing small intestine ...
    CD24 represents the first cell surface marker that facilitates fluorescence-activated cell sorting enrichment of IESCs with widely available antibodies without ...Missing: skin kidney
  62. [62]
    CD24 can be used to isolate Lgr5+ putative colonic epithelial stem ...
    Furthermore, the presence of CD24 expression in normal colonic epithelium may have important implications for the use of anti-CD24-based colorectal cancer ...
  63. [63]
    CD24 expression on human keratinocytes - PubMed
    Its function is not completely known, but it has been suggested that it is involved in cell adhesion and signalling. CD24 has recently been identified as the ...
  64. [64]
    Adult human kidney organoids originate from CD24+ cells and ...
    By electron microscopy, epithelial cells in the tubuloids showed typical features of human adult PT epithelium, including tight and adherens junctions, lumen ...
  65. [65]
    Single-cell atlas of human pancreatic islet and acinar endothelial ...
    Feb 6, 2025 · The overall inflammatory state of T1D is reflected by increased expression of CD74, CD24, class 1 and class 2 HLA, and SPP1 (Fig. 4e, ...
  66. [66]
    CD24 flags anastasis in melanoma cells - PMC - NIH
    Aug 13, 2024 · CD24 is a cell surface marker enriched in a melanoma subpopulation that shows anastasis, where apoptotic cells recover and survive.
  67. [67]
    CD24 and CD44 mark human intestinal epithelial cell populations ...
    While CD24/44 expression is highly restricted to the stem cell zone in the epithelium, there is broad expression in non-epithelial cells in the lamina propria, ...
  68. [68]
    Targeting CD24 as a novel immunotherapy for solid cancers
    Nov 2, 2023 · Cluster Differentiation 24 (CD24), also known as Heat Stable Antigen (HSA), has been extensively studied in the field of immunotherapy, and ...Cd24 As A Cancer Stem Cells... · Linking Cd24 With Signaling... · Regulation Of Cd24...Missing: assigned | Show results with:assigned<|control11|><|separator|>
  69. [69]
    CD24 associates with EGFR and supports EGF/EGFR signaling via ...
    Feb 1, 2016 · CD24 regulates EGFR signaling by inhibiting EGFR internalization and degradation in a RhoA-dependent manner in gastric cancer cells.
  70. [70]
    Surprising magic of CD24 beyond cancer - Frontiers
    CD24 is a glycosylphosphatidylinositol-anchored protein that was first identified in 1978 as a B-cell differentiation antigen (1). It is expressed in a wide ...
  71. [71]
    CD24 and Siglec-10 selectively repress tissue damage ... - PubMed
    Mar 27, 2009 · Our results reveal that the CD24-Siglec G pathway protects the host against a lethal response to pathological cell death and discriminates danger- versus ...
  72. [72]
    Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy
    Jan 27, 2024 · Further evidence that the CD24/SIGLEC-10 axis functions as a "don't eat me" signal in tumor immunity comes from the finding that inhibition of ...
  73. [73]
    CD24 mediates rolling of breast carcinoma cells on P-selectin
    P-selectin mediates rolling of neutrophils and other leukocytes on activated endothelial cells and platelets through binding to P-selectin glycoprotein ...
  74. [74]
    CD24: A Rheostat That Modulates Cell Surface Receptor Signaling ...
    CD24 functions as a rheostat to modulate responses transduced by partnered cell surface receptor(s), and that these partners define the biological outcomes ...
  75. [75]
    [PDF] CD24 Induces the Activation of β-Catenin in Intestinal Tumorigenesis
    May 30, 2016 · We hypothesized that CD24 might promote the activation of the Wnt pathway resulting in translocation of β-catenin into the nucleus. We confirmed ...
  76. [76]
    Hsp70 regulates CD24 expression and promotes metastasis and ...
    Oct 21, 2025 · Hsp70 and CD24 demonstrated interaction through co-precipitation. Knockdown of Hsp70 significantly attenuated CD24 expression (p<0.01) ...
  77. [77]
    CD24 interacts with and promotes the activity of c-src within lipid ...
    GPI-linked proteins including CD24 are often associated with cholesterol-rich lipid raft microdomains in the plasma membrane [24, 25]. To confirm that CD24 is ...
  78. [78]
    CD24-Siglec interactions in inflammatory diseases - PubMed
    May 9, 2023 · SIALYlated CD24 (SialoCD24) is a major endogenous ligand for CD33-family of Siglecs to protect the host against inflammatory and autoimmune diseases.
  79. [79]
    CD24-Siglec interactions in inflammatory diseases - Frontiers
    May 8, 2023 · Nearly 15 years ago, CD24 was shown to interact with Siglec G/10 to selectively inhibit inflammatory response to tissue injuries. Subsequent ...
  80. [80]
    Association between the CD24 Ala57Val polymorphism and risk for ...
    Apr 1, 2015 · The cluster of differentiation 24 (CD24) Ala57Val polymorphism has been implicated as a risk factor for multiple sclerosis (MS) and systemic ...Missing: Ala57 | Show results with:Ala57
  81. [81]
    Analysis of function-associated receptor molecules on peripheral ...
    We found increased expression of the complement receptors 1 (CD35) and 3 (CD11b) and of the activation-associated antigens CD67, CD24, and M5 on synovial fluid ...<|separator|>
  82. [82]
    Accumulation of synovial fluid CD19 + CD24 hi CD27 + B cells was ...
    Sep 1, 2020 · In this study, we investigated whether RA SF CD19 + CD24 hi CD27 + B cells were increased and associated with bone destruction.Missing: upregulated | Show results with:upregulated
  83. [83]
    CD24 is upregulated in inflammatory bowel disease and ... - PubMed
    CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation. Inflamm Bowel Dis. 2010 May;16(5):795-803.Missing: intestinal | Show results with:intestinal
  84. [84]
    CD24 aggravates acute liver injury in autoimmune hepatitis by ...
    Jan 9, 2017 · Here we showed that CD24 deficiency protects mice from concanavalin A (ConA)-induced fulminant liver injury by reducing serum interferon-γ (IFN- ...
  85. [85]
    CD24 is a marker for human breast carcinoma - PubMed
    Our study clearly demonstrates that CD24 is abundantly expressed on cell lines and fresh tissues of breast carcinomas. We find a differential expression of CD24 ...
  86. [86]
    Expression of CD24 in plasma, exosome and ovarian tissue ...
    Jun 10, 2019 · CD24 is a small molecular weight cell-surface protein and an independent marker for poor prognosis in the different type of cancers.
  87. [87]
    CD24, a Novel Cancer Biomarker, Predicting Disease-Free Survival ...
    CD24 expression in NSCLC is associated with ADC histology and disease progression and cancer-related death, indicative of aggressive tumor behavior.
  88. [88]
    Significance of CD44 and CD24 as cancer stem cell markers
    In this critical review, we assess the role of CD44 and CD24 in tumour initiation, development, and metastasis.
  89. [89]
    Early PREdiction of sepsis using leukocyte surface biomarkers
    With logistic regression the optimum biomarker combination was increased neutrophil CD24 and neutrophil CD279, and reduced monocyte HLA-DR expression, but no ...
  90. [90]
    CD24 regulates cancer stem cell (CSC)-like traits and a panel of ...
    Oct 17, 2018 · CD24 has a crucial role in maintaining the urothelial cancer stem-like traits and a panel of CSC-related molecules has potential as a urinary biomarker for non ...
  91. [91]
    Clinical-Bladder cancer Study of urine-based mRNA biomarkers for ...
    Notably, CD24, TOP2A, IQGAP3, UBE2C, and CRH mRNA levels in NMIBC patients were significantly higher than in the hematuria group. In diagnosing low-grade from ...
  92. [92]
    Cluster of Differentiation 24 Polymorphism Has No Significant ... - NIH
    Aug 24, 2022 · Recently, it has been revealed there is an increased risk of multiple sclerosis (MS) in individuals carrying P170TT compared with those ...
  93. [93]
    CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory ... - PubMed
    Jan 29, 2010 · CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus ...
  94. [94]
    Quantitative real-time RT-PCR of CD24 mRNA in the detection of ...
    Mar 15, 2006 · The method has a moderate specificity (47.3%) but a high sensitivity (86.4%) if the cutoff is set at 0.0498. CD24 expression levels among Pca ...
  95. [95]
    Targeting CD24 in Cancer Immunotherapy - PMC - NIH
    CD24 has been identified as a promising target for cancer immunotherapy, and targeting it with antibody drugs could offer effective treatment options.
  96. [96]
    Antibody targeting of CD24 efficiently retards growth and influences ...
    Mar 19, 2013 · We found that SWA11 mAb treatment strongly altered the intratumoural cytokine microenvironment. The addition of SWA11 mAb to gemcitabine ...In Vivo Xenograft Tumour... · Angiogenesis Protein Array · Net Antibody Uptake Assay
  97. [97]
    A first-in-human phase I study of ATG-031, anti-CD24 antibody, in ...
    May 29, 2024 · ATG-031 is a first-in-class humanized cluster of differentiation 24 (CD24) antibody. By disrupting the interaction between CD24, a 'do not eat me' signal on ...
  98. [98]
    FDA Grants Fast Track Status to PHST001 in Ovarian Cancer
    Jun 11, 2025 · The FDA recently granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody, for the treatment of advanced ovarian cancer.Missing: NCT | Show results with:NCT
  99. [99]
    NCT06840886 | A Study of PHST001 in Advanced Solid Tumors
    A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved ...
  100. [100]
    CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy ...
    CD24-targeted CAR-T cells mediated long-term antitumor efficacy through activation of endogenous tumor immune responses.
  101. [101]
    Checkpoint CD24 function on tumor and immunotherapy - Frontiers
    In 1990, the CD24 gene of humans was first cloned, homolog to the mouse CD24a (12). The gene sequence for CD24 can be found in at least five different locations ...<|control11|><|separator|>
  102. [102]
    CD24 is a novel target of chimeric antigen receptor T cells for the ...
    Jul 7, 2023 · This study proved that CD24-specific CAR-T cells have potent anti-tumor activity and potential application value in treatment of TNBC.
  103. [103]
    Targeting CD24 for treatment of ovarian cancer by short hairpin RNA
    Administration with CD24–shRNA in vivo suppressed tumor volume increase by microvessel density (MVD) decrease, cell proliferation inhibition and apoptosis ...
  104. [104]
    Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of ...
    May 12, 2016 · As our recent data showed that silencing CD24 restores at least part of the tumor suppressor activity of mutant p53 in prostate cancer cells (6) ...